Search Results - "FRIEDLAND, David M"

Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies by ZAMBONI, William C, RAMALINGAM, Suresh, FRIEDLAND, David M, EDWARDS, Robert P, STOLLER, Ronald G, STRYCHOR, Sandra, MARUCA, Lauren, ZAMBONI, Beth A, BELANI, Chandra P, RAMANATHAN, Ramesh K

“…Purpose: S-CKD602 is a pegylated liposomal formulation of CKD602, a semisynthetic camptothecin analogue. Pegylated (STEALTH) liposomes can achieve extended…”
Get full text

Long‐term survivors after gamma knife radiosurgery for brain metastases by Kondziolka, Douglas, Martin, Juan J., Flickinger, John C., Friedland, David M., Brufsky, Adam M., Baar, Joseph, Agarwala, Sanjiv, Kirkwood, John M., Lunsford, L. Dade

“…BACKGROUND Stereotactic radiosurgery, with or without whole‐brain radiation therapy, has become a valued management choice for patients with brain metastases,…”
Get full text

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies by Ramalingam, Suresh S, Egorin, Merrill J, Ramanathan, Ramesh K, Remick, Scot C, Sikorski, Rachel P, Lagattuta, Theodore F, Chatta, Gurkamal S, Friedland, David M, Stoller, Ronald G, Potter, Douglas M, Ivy, S Percy, Belani, Chandra P

“…Background: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) inhibits heat shock protein 90, promotes degradation of oncoproteins, and exhibits synergy with…”
Get full text

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer by Tarhini, Ahmad A., Rafique, Imran, Floros, Theofanis, Tran, Phu, Gooding, William E., Villaruz, Liza C., Burns, Timothy F., Friedland, David M., Petro, Daniel P., Farooqui, Mariya, Gomez‐Garcia, Jose, Gaither‐Davis, Autumn, Dacic, Sanja, Argiris, Athanassios, Socinski, Mark A, Stabile, Laura P., Siegfried, Jill M.

“…BACKGROUND Activation of the mesenchymal‐epidermal transition factor (MET) tyrosine kinase and its ligand, hepatocyte growth factor (HGF), is implicated in…”
Get full text

First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC by Ancevski Hunter, Katerina, Friedland, David M, Villaruz, Liza C, Burns, Timothy F

Get more information

Bevacizumab and irinotecan therapy in glioblastoma multiforme : a series of 13 cases by ALI, Sheikh A, MCHAYLEH, Wassim M, AHMAD, Asif, SEHGAL, Rajesh, BRAFFET, Molly, RAHMAN, Mohsin, BEJJANI, Ghassan, FRIEDLAND, David M

“…Endothelial proliferation has been recognized as a marker of high-grade or aggressive glioma. Bevacizumab is a humanized immunoglobulin G1 monoclonal antibody…”
Get full text

Extraosseous Osteosarcoma of the Esophagus: A Case Report by Wegner, Rodney E., McGrath, Kevin M., Luketich, James D., Friedland, David M.

“…Extraosseous osteosarcoma (EOO) is a malignant mesenchymal neoplasm that is located in the soft tissues without direct attachment to the skeletal system and…”
Get full text

Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies by Wu, Huali, Ramanathan, Ramesh K., Zamboni, Beth A., Strychor, Sandra, Ramalingam, Suresh, Edwards, Robert P., Friedland, David M., Stoller, Ronald G., Belani, Chandra P., Maruca, Lauren J., Bang, Yung-Jue, Zamboni, William C.

“…S-CKD602 is a pegylated long-circulating liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. A population pharmacokinetic (PK) model for…”
Get full text

Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer by Bernard, Mark E, Glaser, Scott M, Gill, Beant S, Beriwal, Sushil, Heron, Dwight E, Luketich, James D, Friedland, David M, Socinski, Mark A, Greenberger, Joel S

“…We determined factors associated with morbidity and outcomes of a series of non-small cell lung cancer (NSCLC) patients treated with dose-escalated…”
Get full text

Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors by ZAMBONI, William C, JUNG, Laura L, RUZHI JIN, STRYCHOR, Sandra, VOZNIAK, Michael, TROETSCHEL, Monica, RAMANATHAN, Ramesh K, EGORIN, Merrill J, POTTER, Douglas M, FRIEDLAND, David M, BELANI, Chandra P, AGARWALA, Sanjiv S, WONG, Michael M. W, FAKIH, Marwan, TRUMP, Donald L

“…Purpose: 9-Nitrocamptothecin (9NC) is an oral camptothecin analogue currently administered at 1.5 mg/m 2 /day × 5 days/week in Phase III studies for pancreatic…”
Get full text

Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors by Zamboni, William C., Maruca, Lauren J., Strychor, Sandra, Zamboni, Beth A., Ramalingam, Suresh, Edwards, Robert P., Kim, JK, Bang, YJ, Lee, HY, Friedland, David M., Stoller, Ronald G., Belani, Chandra P., Ramanathan, Ramesh K.

“…Background: STEALTH® liposomal CKD-602 (S-CKD602), a camptothecin analog, is eliminated by the reticuloendothelial system (RES), which consists of cells,…”
Get full text

Radiosurgery for the treatment of spinal lung metastases by Gerszten, Peter C., Burton, Steven A., Belani, Chandra P., Ramalingam, Suresh, Friedland, David M., Ozhasoglu, Cihat, Quinn, Annette E., McCue, Kevin J., Welch, William C.

“…BACKGROUND. Spinal metastases are a common source of pain as well as neurologic deficit in patients with lung cancer. Metastases from lung cancer traditionally…”
Get full text

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy : E4896, an eastern cooperative oncology group study by DUTCHER, Janice P, LEON, Larry, MANOLA, Judith, FRIEDLAND, David M, ROTH, M. Bruce, WILDING, George

“…The current study evaluated the response rate and 6-month time to disease progression of the antiangiogenesis agent carboxyamidotriazole (CAI) in patients with…”
Get full text

Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients by Wu, Huali, Ramanathan, Ramesh K, Zamboni, Beth A, Strychor, Sandra, Ramalingam, Suresh, Edwards, Robert P, Friedland, David M, Stoller, Ronald G, Belani, Chandra P, Maruca, Lauren J, Bang, Yung-Jue, Zamboni, William C

“…S-CKD602 is a PEGylated liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. The objective of this study was to characterize the bidirectional…”
Get full text

Renal Cell Carcinoma from a Transplanted Allograft: Two Case Reports and a Review of the Literature by McHayleh, Wassim, Morcos, John P, Wu, Tong, Shapiro, Ron, Yousem, Samuel, Appleman, Leonard, Friedland, David M

“…Abstract We report 2 cases of renal cell carcinoma (RCC) in which the tumor arose from a transplanted allograft. The first case is a 52-year-old man with a…”
Get full text

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies by RAMANATHAN, Ramesh K, RAMALINGAM, Sakkaraiappan, SHIN, Dong M, CHATTA, Gurkamal S, TUTCHKO, Susan, ZAMBONI, William C, EGORIN, Merrill J, BELANI, Chandra P, POTTER, Douglas M, FAKIH, Marwan, JUNG, Laura L, STRYCHOR, Sandra, JACOBS, Samuel A, FRIEDLAND, David M

“…Capecitabine in combination with docetaxel given every 3 weeks has shown a high degree of activity in a number of tumor types, but at the expense of…”
Get full text

Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors by Kovatich, Albert, Friedland, David M., Druck, Teresa, Hadaczek, Piotr, Huebner, Kay, Comis, Robert L., Hauck, Walter, McCue, Peter A.

“…BACKGROUND The origins of and interrelations between low grade and high grade neuroendocrine lung tumors, typical and atypical carcinoids, and small cell lung…”
Get full text

A Phase II Evaluation of Weekly Paclitaxel Plus Carboplatin in Advanced Urothelial Cancer by Friedland, David M., Dakhil, Shaker, Hollen, Charles, Gregurich, Mary Ann, Asmar, Lina

“…This Phase II trial was designed to evaluate the overall objective response rate, complete response rate, efficacy, and safety of weekly paclitaxel (Taxol®)…”
Get full text

Stereotactic radiosurgery for spinal metastases from renal cell carcinoma by GERSZTEN, Peter C, BURTON, Steven A, OZHASOGLU, Cihat, VOGEL, William J, WELCH, William C, BAAR, Joseph, FRIEDLAND, David M

“…The role of stereotactic radiosurgery in treating renal cell carcinoma (RCC) metastases to the spine has previously been limited. In this study the authors…”
Get full text

A Phase I Study of17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies by RAMALINGAM, Suresh S, EGORIN, Merrill J, IVY, S. Percy, BELANI, Chandra P, RAMANATHAN, Ramesh K, REMICK, Scot C, SIKORSKI, Rachel P, LAGATTUTA, Theodore F, CHATTA, Gurkamal S, FRIEDLAND, David M, STOLLER, Ronald G, POTTER, Douglas M

Get full text